Moningi, Shalini
Choudhury, Atish D.
Martin, Neil E.
Nguyen, Paul L.
D’Amico, Anthony V.
Cagney, Daniel N.
Leeman, Jonathan E. http://orcid.org/0000-0003-4539-0762
Article History
Received: 3 August 2023
Accepted: 26 September 2023
First Online: 4 November 2023
Declarations
:
: ADC: Honoraria: OncLive, Bayer, Targeted Oncology, Aptitude Health, Journal of Clinical Pathways, Cancer Network, Clinical Care Options, Great Debates & Updates, Pfizer, Springer Healthcare; Consulting: Blackstone; Advisory Board: Clovis, Dendreon, Bayer, Eli Lilly, AstraZeneca, Astellas, Blue Earth, Janssen, Tolmar; Research Funding: Bayer, PLN: grants and/or personal fees from Astellas Pharma, Bayer, Boston Scientific, Janssen Pharmaceuticals, Myovant, Nanocan, Dendreon, Ferring, COTA, Blue Earth Diagnostics, Augmenix, and Novartis Pharma; and stock options with Nanocan. JEL: Research funding from Viewray, NH Theraguix and Varian.
: This study was approved by our institutional IRB committee.
: All prospective study participants, or their legal guardian, provided informed written consent prior to study enrollment.